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The variation in cystic fibrosis (CF) lung disease and development of CF related complications correlates poorly with the genotype of the
CF transmembrane regulator (CFTR) and with environmental factors. Increasing evidence suggests that phenotypic variation in CF can be
attributed to genetic variation in genes other than the CFTR gene, so-called modifier genes.
In recent years, multiple candidate modifier genes have been investigated in CF, especially genes that are involved in the control of
infection, immunity and inflammation. Some of these genes have been rather conclusively identified as modifiers of the CF phenotype,
whereas associations found in other genes have not been confirmed or are conflicting.
Identification of genetic variation in modifier genes, obtained by genotype–phenotype studies in well-defined patient populations, may be
used as an aid to prognosis and may provide the possibility of new therapeutic interventions.
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lectin1. Introduction
The clinical course of cystic fibrosis (CF) varies
widely. Whereas some individuals die early in childhood,
others live well in adulthood suffering from with only
mild lung disease [1]. Before the identification of the CF
gene in 1989, it was assumed that variation in the
severity of disease was due to allelic variation in the gene
defective in CF, the Cystic Fibrosis Transmembrane
Conductance Regulator (CFTR) gene [2]. CFTR is a
multi-domain protein with a complex regulation. It is a
small chloride channel that is found at the apical border
of epithelial cells lining most exocrine glands [2]. More
than 1350 mutations in the CFTR gene have been
identified so far [3].1569-1993/$ - see front matter D 2005 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2005.05.006
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Mutations in the CFTR gene can disrupt CFTR function
by different mechanisms depending on their nature and on
the domain in which these alterations occur [2]. Based on
these observations, CFTR mutations are subdivided into five
classes [4,5].
Class I mutations are mutations causing premature
termination signals, typically resulting in little or no protein
production. Class II mutations, such as DF508, result in the
production of an abnormally folded CFTR that is not
trafficked normally to the apical cell membrane. Class III
mutations produce proteins that are inserted in the apical cell
membrane but have a defective regulation, mostly because of
mutations in the nucleotide-binding domains. Class IV
mutations affect amino acids located in the pore of the
channel, which will give rise to a chloride channel with a
normal regulation, but with reduced single channel currents.
Class V mutations affect splicing of CFTR transcripts and
result in significantly decreased production of normal CFTR.is 4 (2005) 7 – 13ed by Elsevier B.V. All rights reserved.
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Class VI mutations harbor nucleotide alterations that affect
the regulatory properties of the CFTR protein (e.g., towards
other ion channels like ENaC or ORCC) [2]. Lastly, some
mutations will disrupt the function of the CFTR in more
than one way, and will therefore have to be categorized in
different mutation classes [2].
A clear correlation is observed between CFTR genotype
and pancreatic exocrine insufficiency: CFTR mutation
classes I, II, and III are associated with significant declines
in CFTR expression or function and are invariably associated
with pancreatic exocrine insufficiency [6]. CFTR mutation
classes IV and Vare associated with some residual epithelial
cell CFTR function and are often associated with pancreatic
exocrine sufficiency [7,8]. A recent retrospective cohort
study on more than 10,000 patients enrolled in the US CF
Foundation National Registry demonstrated a significantly
lower mortality rate in patients with class IV and V mutation
compared with class II [8]. Patients with class IV and V
mutations also showed a higher forced expiratory volume in
one second (FEV1) and forced vital capacity (FVC), a higher
height and weight and less P. aeruginosa colonization.
Patients with class I, II and III mutations all showed similar
clinical characteristics. However, although patients with
class IVand V mutations showed a milder clinical phenotype
and significantly lower mortality rates, variation in the
severity of disease was found to be only partially related with
allelic variation in CFTR. There is substantial phenotypic
variability within patients having the same CFTR mutation
class and even identical mutations. Thus, other factors
modify the CF phenotype.3. Other factors associated with CF phenotype
A great number of environmental factors such as P.
aeruginosa [9], B. cepacia [10], nutritional support [11],
early (antibiotic) treatment [12,13], tobacco use [14] and
socioeconomic status [15] have been shown to be associated
with the phenotype of CF. However, these factors can
insufficiently account for the degree of variability observed
in individuals with identical CFTR phenotypes. Even
siblings and twins with identical CFTR genotypes and
sharing mainly the same environment show different disease
severity [16]. Monozygous twins have a significantly higher
concordance of nutritional status and severity of lung
disease than dizygous twins, suggesting that CF disease
severity is modulated by secondary genetic factors besides
the CFTR gene itself [1,16]. These secondary genetic
factors are called modifier genes or gene modifiers [17,18].4. Modifier genes
Modifier genes in monogenic diseases are genes other
than the single mutated gene, which affect disease expres-sion. Modifier genes can affect disease expression via several
ways. They can be involved in intracellular processes in the
cell where the causal or primary gene (e.g., CFTR gene) is
expressed [17]. Products of modifier genes can affect
splicing, transcription, translation, protein trafficking, gly-
cosylation or other posttranslational processes, but also
protein expression, degradation or secretion [17].
Alternatively, modifier genes may exert its action in
cells in which no expression of the primary gene takes
place [17]. The expression of modifier genes may regulate
responses like inflammation, fibrosis, host defense, ion
transport, or virtually any other response to a disturbance
of homeostasis [17].
Nowadays, one of the most common methods to study
associations between genetic variation in Fcandidate_ modi-
fier genes and clinical phenotype is the identification of
single nucleotide polymorphisms (SNPs) [19]. SNPs are
single base pair positions in the genome at which variation
in nucleotides gives rise to alternative alleles in normal
individuals and populations [20]. In contrast to gene
mutations occurring in less than 1% of the individuals in a
population, SNPs are present in more than 1% of the
individuals and comprise common genetic variation in
normal individuals. Evidence of linkage between a SNP
and disease phenotype indicates that the SNP is located in a
modifier gene or that the SNP is in linkage with a modifier
gene. Functional SNPs altering disease phenotype are, for
instance, an SNP in the promoter region of a modifier gene
affecting the transcription rate, an SNP in an exon affecting
protein structure or function, and an SNP within an intron
interfering with splicing mechanisms [20].5. Modifier genes in CF
Modifier genes may influence the severity of CF
phenotypes through a variety of mechanisms. They may
modulate the phenotype by acting on the basic molecular
level, such as providing alternative chloride conductance,
and regulating splicing and expression of the CFTR gene.
They may also modulate susceptibility to infection and
inflammatory response. Furthermore, CF pulmonary pheno-
type may be modified by genes associated with mucociliary
clearance and epithelial tissue damage and repair. Finally,
gastrointestinal injury (liver, pancreas, intestine) in CF may
be influenced by genes modulating proteolysis and fibrosis.
Several genes investigated as potential modifier genes of
CF phenotype will be summarized below. In Tables 1 and 2,
potential modifiers of pulmonary and gastrointestinal
phenotype are displayed.
5.1. Mannose-binding lectin (MBL)
MBL is a serum protein participating in innate immune
defense [21,22]. MBL activates the complement system by
MBL-associated serine proteases and may interact with
Table 1
Potential pulmonary modifier genes investigated in CF
Gene Author N pat Polymorphism FEV1 CXR PA BC Mortality
MBL Garred et al. [21] 149 A/0+X/Y  0 ++ ++
Davies et al. [23] 558 A/0+X/Y  0 0
Gabolde et al. [24] 164 A/0  0
Yarden et al. [25] 179 A/0+X/Y  0
NOS1 Grasemann et al. [31] 75 AATn12 0 ++
Grasemann et al. [30] 40 AATn12 0 ++
Texereau et al. [32] 59 GTn>27 + 0 0
NOS3 Grasemann et al. [28] 70 894G/T 0 +a
AAT Doring et al. [34] 215 M/S,Z 0 ++
Meyer et al. [35] 269 M/S,Z 0
Mahadeva et al. [33] 157 M/S,Z + 0 0 0
Mahadeva et al. [59] 79 M/S,Z 0
Frangolias et al. [37] 716 M/S,Z 0 + 0 0
716 1237G/A 0 0 0 0
Henry et al. [36] 124 1237G/A + ++ 
HLA-II Aron et al. [39] 98 DR4/+ 0 
98 DR7/+ 0 +
TNF-a Hull and Thomson [44] 53 308G/A  0 0
GST M1 Hull and Thomson [44] 53 A,B/0 0  0
GST M3 Flamant et al. [45] 146 A/B + 0
TGF h1 Arkwright et al. [47] 171 869T/C + 0 0 0
ACE Arkwright et al. [48] 261 D/I + 0 0 0
h2AR Buscher et al. [49] 126 16R/G  0
CLC-2 Blaisdell et al. [54] 31 Various 0
Abbreviations: N pat—number of patients; FEV1—forced expiratory volume in one second; CXR—chest X-ray; PA—P. aeruginosa colonization; BC—B.
cepacia colonization; MBL—mannose-binding lectin; NOS—nitric oxide synthase; AAT—a1-antitrypsin; HLA—human leukocyte antigen gene II; TNF-a—
tumor necrosis factor-a; GST—gluthatione S-transferase; TGF-h1—transforming growth factor-h1; ACE—angiotensin 1 converting enzyme; h2AR—h2
adrenoreceptor; CLC-2—chloride channel-2.
Symbols: ++, strongly positive association ( p <0.01); +, positive association ( p <0.05); 0, no significant association; , negative association ( p <0.05);  ,
strongly negative association.
a In females only.
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mannose and N-acetylglucosamine oligosaccharides, are
present on a wide variety of microorganisms. Human
MBL is derived from a single gene on chromosome 10,
MBL2. In exon 1 of the MBL2 gene, 3 single-baseTable 2
Potential gastro-intestinal modifier genes investigated in CF
Gene Author Ref N pat Poly
MBL Gabolde et al. [26] 216 A/0
AAT Mahadeva et al. [33] 157 M/S
HLA-II Carrington et al. [40] 67 DQB
Lanng et al. [41] 57 DR3
Duthie et al. [42] 274 DQ6
TNF-a Hull and Thompson [44] 53 30
GST M1 Hull and Thompson [44] 53 A,B
GST M3 Flamant et al. [45] 146 A/B
GST P1 Henrion-Caude et al. [46] 106 105
ACE Arkwright et al. [48] 261 D/I
HFE Rohlfs et al. [50] 89 C28
Devaney et al. [51] 122 C28
ATB0 Larriba et al. [53] 48 Vari
Abbreviations: N pat—number of patients; LD—liver disease; MI—meconium i
leukocyte antigen gene II; TNF-a—tumor necrosis factor-a; GST—gluthatione S
converting enzyme; HFE—putative hereditary hemochromatosis gene; ATB0—ne
Symbols: ++, strongly positive association ( p <0.01); +, positive association ( p <0
strongly negative association.substitutions independently cause low serum levels of
MBL [21,22]. The normal (wild-type) allele has been
designated A, whereas the common designation for the
variant alleles (B, C, D) is 0. Even in heterozygotes, each of
the 3 variants reduces the amount of functional MBLmorphism LD Diabetes MI Weight
++
,Z 0
1 Asp57/+ 
, DR4 0
/+ +
8G/A 
/0 0
0
I/V  
 0
2Y 0
2Y 0
ous 0
leus; MBL—mannose-binding lectin; AAT—a1-antitrypsin; HLA—human
-transferase; TGF-h1—transforming growth factor-h1; ACE—angiotensin 1
utral amino acid transporter B0.
.05); 0, no significant association; , negative association ( p <0.05);  ,
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alleles, several nucleotide substitutions in the promoter
region of the MBL2 gene affect the MBL serum level.
Particularly, a polymorphism in codon 221 (X/Y type) has
a significant down-regulating effect on serum MBL serum
concentrations [21].
It has been shown that MBL variant alleles resulting in
low functional MBL serum levels are associated with an
increased risk of different types of infections that occur
primarily in children, but also in adults. Moreover, MBL
deficiency has also been shown to play a role in auto-
immune diseases [21]. In all 4 published studies concerning
CF patients, a significantly reduced lung function was found
in carriers of MBL 0 alleles when compared with AA
homozygotes [21,23–25]. In one study, carriers of variant
alleles were found to be more frequently colonized with B.
cepacia [21], whereas in another study, patients homozy-
gous for variant alleles had a nearly significantly higher
frequency of colonization by P. aeruginosa [24]. This,
however, was not confirmed in 2 other studies [23,25].
Finally, associations between allelic variants of MBL and
the presence of liver cirrhosis and survival have been
described [21,26]. In conclusion, the MBL gene appears to
be a well validated modifier of CF phenotype.
5.2. Nitric oxide synthase (NOS)
Nitric oxide (NO) has been shown to be important in a
variety of regulatory processes in the lung, including host
defense, inflammation, and bronchomotor control [27].
Three isoforms of NO synthases (NOSs) exist: neuronal
NOS (NOS1), inducible NOS (NOS2), and endothelial NOS
(NOS3). NOS1 and NOS3 are constitutively expressed in
various cell types, whereas NOS2 is regulated by cytokines
primarily at the level of gene transcription [28].
Exhaled NO levels are elevated in individuals with
inflammatory lung diseases, such as asthma and bronchio-
litis compared with healthy controls [27,29]. In contrast,
despite the inflammatory nature of CF lung disease, NO
levels in exhaled air from CF patients are lower than those
from healthy controls and individuals with other inflam-
matory lung diseases [27,29], as described in [60].
Recently, Grasemann demonstrated the number of AAT
repeats in the NOS1 gene to be negatively associated with
nasal and expired NO in CF patients [30,31]. Furthermore,
CF patients with a high number of AAT repeats were
more frequently colonized with P. aeruginosa and A.
fumigatus. In another population, an association between
the number of GT repeats in the promoter region of the
NOS1 gene and higher exhaled NO levels and less decline
in lung function was observed [32]. Grasemann’s group
also found an association between a common polymor-
phism (G847T) in the NOS3 gene, higher exhaled NO
levels and a decreased risk for colonization with P.
aeruginosa in females [28]. This finding was not found
in males and the total population. In conclusion, at leastthe NOS1 gene seems to be a significant modifier of
pulmonary phenotype in CF.
5.3. a1-Antitrypsin (a1-AT)
A major cause of the chronic pulmonary disease in CF
is a persistent imbalance between neutrophil proteinases,
most importantly elastase, and anti-proteinases, in partic-
ular a1-AT [33]. a1-AT is an acute-phase glycoprotein and
is the most important proteinase inhibitor in the lung. The
most clinically important variants are the common S
(264GluYVal) and Z (342GluYLys) alleles which are
found in approximately 12% of the population. They
result in plasma a1-AT levels in the homozygote state of
60% and 10%, respectively, when compared with the
normal MM homozygote [33]. Another polymorphism in
the 3’ non-coding region enhancer-binding element of the
a1-AT gene (G1237A) may reduce the rise in the level of
a1-antitrypsin during the acute phase response, whilst
leaving baseline levels unaffected [33].
Doring et al. found an earlier age of chronic P.
aeruginosa acquisition in CF patients who carried a1-AT
deficiency alleles [34], but this could not be confirmed by
Meyer et al. [35]. Doring et al. did not find an association
between deficiency and lung function [34], but in another
study, in which was adjusted for age, a significantly better
lung function was found in patients with a deficient
genotype (M, S, Z) compared with patients with a normal
phenotype [33]. In the latter study, no association between
the G1237A polymorphism and lung function was found.
On the other hand, in a study by Henry et al., this
polymorphism was associated with a better lung function
and less change in X-ray score and fewer infective
exacerbations [36]. Finally, in a large recent Canadian
study (n = 716), one of the few that adjusted for
confounders, none of the associations between deficiency
Z and S genotypes or G1237A polymorphisms, and lung
function or age of P. aeruginosa colonization could be
confirmed [37]. It thus can be concluded that, despite the
considerable amount of data, the impact of a1-AT on CF
phenotype is still unclear.
5.4. Human leukocyte antigen (HLA) system
The HLA system is the human version of the major
histocompatibility complex (MHC). It controls quantitative
and qualitative aspects of immune responses. Certain HLA
alleles have shown to be associated with increased
susceptibility to infectious diseases, higher risk of auto-
immune diseases and development of cancer [38]. One
study in CF patients demonstrated that colonization with P.
aeruginosa was significantly less likely among HLA DR4
carriers, whereas carriers of the DR7 allele were more
likely colonized with P. aeruginosa and showed higher
IgE levels [39]. No association with lung function or nasal
polyposis was found. Associations with HLA genotype
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Asp57) and liver disease (DQ6) [40–42].
5.5. Tumor necrosis factor-a (TNF-a)
TNF-a is a pro-inflammatory cytokine found in high
concentration in the lungs of patients with CF [43]. A TNF-
a promoter gene polymorphism (G-308A) is associated with
higher constitutive and inducible levels of transcription of
TNF-a. CF patients carrying a G-308A polymorphism were
demonstrated to have a significantly lower lung function
and body weight compared with patients without this
polymorphism [44].
5.6. Glutathione S-transferases (GST)
Glutathione is the major local pulmonary anti-oxidant
and is present in high concentrations in the epithelial lining
fluid. GSTs detoxify harmful organic hydroperoxides which
are generated as a result of exposure to oxidant stress, such
as that found in the lungs of CF patients. GSTs conjugate the
hydroperoxides with glutathione, thereby preventing further
pulmonary damage [44]. One gene in this anti-oxidant
family, GST M1, has a common non-functioning allele
(GST M1-0). CF patients homozygous for this allele have
worse chest radiographic scores and worse Shwachman
scores of disease severity [44]. Another association has been
found between a variant genotype consisting of a three-base
pair deletion for GST M3 and better lung function [45].
Finally, a polymorphism in GST P1 (Ile105Val) was shown
to be associated with liver disease [46].
5.7. Transforming growth factor-b1 (TGF-b1)
TGF-h1 is a cytokine with both pro-inflammatory and
anti-inflammatory properties that promotes the proliferation
of fibroblasts and the deposition of collagen. A poly-
morphism (T869C) resulting in lower production of TGF-h1
was shown to result in a slower deterioration in lung
function in CF patients [47].
5.8. Angiotensin I converting enzyme (ACE)
ACE is another pro-inflammatory molecule, activated by
TGF-h1, and may have a role in the development of more
severe organ damage. A polymorphism in ACE, consisting of
the presence (I) or absence (D) of a 250-bp DNA fragment, is
associated with serum ACE level. A high-producer ACE
genotype (DD) in CF patients was found to be associated with
patient’s age at which FEV1 became lower than 50% of
predicted and with the development of liver cirrhosis [48].
5.9. Other modifier genes
Apart from modifier genes involved in host defense and
inflammation, also a number of other modifier genes havebeen described. h2-Adrenoreceptors (h2AR) are important
mediators of cyclic AMP in the airway. They may modify
the CFTR activity in CF patients with mutations that have
residual function of CFTR (e.g., DF508). For instance, one
h2AR polymorphism (R16G) was shown to be related with
reduced lung function and a greater decline in lung
function [49].
In two studies, CF patients, meconium ileus (MI) was
observed more frequently in carriers of a polymorphism
(C282Y) in the gene for hemochromatosis (HFE) compared
with patients without MI (19% vs. 10% and 31% vs. 13%,
respectively). In both studies, this finding did not reach
statistical significance [50,51].
A very strong association was found between a locus on
chromosome 19q13, called CFM1, and meconium ileus
(MI) [52]. The human CFM1 locus is in closest linkage with
a gene coding for a Na+-dependent neutral amino acid
transporter called ATB0, also named SLC1A5 [53]. How-
ever, no association between MI and a particular allele or
haplotype in ATB0 could to be demonstrated [53].
Finally, genes coding for chloride channels besides the
CFTR are potential modifier genes. CLC-2 is one candidate
alternative chloride channel, which is located in respiratory
epithelia. However, polymorphisms in the CLC-2 gene do
not seem to be correlated with severity of lung disease [54].6. Interpretation of results of modifier gene studies
It can be noticed that the majority of studies on modifier
genes in CF are on rather small numbers of patients, most of
the time not repeated and if so, often having conflicting
results. When interpreting results of modifier genes studies,
the following needs to be taken into account.
Firstly, in modifier gene studies, a good definition and
ascertainment of the phenotype are crucial. Without careful
definition of the phenotype, both false negative and false
positive results may occur [17]. For example, outcomes of
modifier gene studies on associations with P. aeruginosa
may differ because of differences in the frequency and the
type of culture. Furthermore, definitions of CF related
complications like diabetes or liver cirrhosis are not
consistent. Also, many outcomes for lung function are used
(cross-sectional vs. longitudinal decline, dichotomization,
Fsevere_ vs. Fmild_) [17]. Many studies are unable to confirm
the results of previous studies due to these inconsistent
phenotype definitions.
Secondly, modifier gene studies will provide associations
but chance associations will certainly occur because of the
number of comparisons that will be possible [55]. Modifier
gene studies provide an association between a genetic
polymorphism and disease phenotype, However, they do not
demonstrate a causal (i.e., functional or physiological)
relationship between a SNP and a phenotype. It seems
therefore mandatory to establish the functional relationship
between SNP and phenotype [17,55].
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neously with other potential modifier genes [17]. Interaction
can occur between candidate modifier genes, for example,
when they act in the same biologic pathway [1]. A valid
association between a modifier gene and a certain phenotype
should hold up under simultaneous testing of genes [17,48].
However, the possibility of testing of interactions is often
limited by study size.
Fourthly, each modifier gene should be adjusted for poten-
tial confounders, including age, sex, age of CF diagnosis,
CFTR genotype, pancreatic sufficiency status, body mass
index and infection with P. aeruginosa [37]. Lack of adjust-
ment for these confoundersmay result in spurious associations.
Finally, reported associations should be replicated in
large independent populations. Large nationwide multi-
center studies on modifier genes in CF are now performed,
for example, by the Canadian Consortium for CF Modifier
Gene Studies which has already enrolled over 1300
Canadian CF families [56] and the US Gene Modifier
Study Group which has enrolled over 800 subjects [57].
These large studies will have enough statistical power to
establish valid associations between potential modifier
genes and CF phenotype found in previous smaller studies.7. Applications and perspectives of modifier gene studies
Using a multivariate model including clinical patient
characteristics and a number of modifier genes, the clinical
course of pulmonary disease or the development of CF rela-
ted complications like diabetes and liver cirrhosis may be
predicted. Thus, one of the potential applications of the re-
sults of modifier gene studies is an aid to prognosis. Patients
found to be at high risk for a complication can be more often
and more intensively screened and treatment of this com-
plication can be started before symptoms have developed.
Furthermore, modifier gene studies will lead to a better
understanding of CF pathophysiology and provide the
possibility of new therapeutic interventions [1]. The identi-
fication of genes that influence CF phenotype illuminates
therapeutic targets, either the protein product of the gene or
the entire pathway in which it acts. Therapeutic interventions
can be developed to minimize the consequences and enhance
the benefits of modifier genes of CF phenotype [18,55]. A
case report of such a successful intervention has already been
published: infusion of MBL in a CF patient known to carry
MBL-deficient alleles [58]. In the future, similar therapies
based on modifier gene genotyping in individuals with CF
may become an important part of CF treatment regimens [1].Acknowledgement
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